Safety and Efficacy Comparison of Atorvastatin Versus Rosuvastatin in Management of Lipid Profile in Patients Diagnosed with Type-2 Diabetes Mellitus and Obesity

Abstract

The objective of the present study is to evaluate and compare the safety and efficacy comparison of the effect on Fasting Blood Sugar (FBS), Post Lunch Blood Sugar (PLBS), Hemoglobin A1c (HbA1c), Serum Creatinine, Lipid Profile [Low density Lipoprotein (LDL), Very Low-Density Lipoprotein (VLDL), High Density Lipoprotein (HDL), Triglycerides (TG), Total Cholesterol (TC)] of Atorvastatin (A) and Rosuvastatin (R) in Type 2 Diabetes Mellitus (T2DM) and Obese patients. It is a Prospective, Observational & multicentric comparative study conducted in Patients with T2DM and in patients with Obesity in Warangal, Telangana state. The Study Protocol, Data Collection Sheet were submitted. A total of 903 patients were screened for the study, out of 903 patients 610 patients are T2DM and 293 patients are Obese. Results obtained from the study in T2DM group patients indicate that Atorvastatin as well as Rosuvastatin has significant effect on reducing LDL levels (for A 160.82 ± 24.39 to 107.57 ± 18.67; for R 162.49 ± 29.37 to 85.51 ± 17.30), reducing TC levels (for A 213.48 ± 36.02 to 156.59 ± 30.90; for R 223.40 ± 34.65 to 141.69 ± 23.26), reducing TG levels (for A 182.91 ± 43.57 to 129.64 ± 29.13; for R 183.65 ± 52.44 to 115.48 ± 29.43) and elevating HDL levels (for A 35.70 ± 5.01 to 49.32 ± 5.38; for R 34.88 ± 4.91 to 48.59 ± 5.38) and in obese group patients indicate that has significant effect on reducing LDL levels (for A1 58.57 ± 21.29 to 123.66 ± 18.95; for R 160.02 ± 32.67 to 102.91 ± 22.20), reducing TC levels (for A 208.68 ± 32.84 to173.96 ± 32.59; For R 210.09 ± 33.79 to 156.17 ± 24.13), reducing TG levels (for A 174.88 ± 40.15 to 139.80 ± 33.23 ; for R 172.64 ± 37.40 to 117.63 ± 30.87), elevating HDL levels (for A 34.83 ± 3.79 to 45.99 ± 3.92; for R 35.54 ± 4.85 to 47.83 ± 6.34). In consideration of the Safety parameters, the most common adverse events in T2DM group patients are: Atorvastatin reported Myalgia, Rosuvastatin reported Headache in high number, whereas in Obese group patients Atorvastatin reported Myalgia, Abdominal bloating, Headache, Rosuvastatin reported Headache, Pain in high number. Conclusion: Thus, this study shows that Rosuvastatin should be prescribed over Atorvastatin in Type 2 Diabetes Mellitus patients and in obese patients in whom LDL, HDL, TG and TC levels are deviated from normal reference values.